Products
Tidutamab Biosimilar Bispecific Antibody (SSTR2 × CD3) for Research
Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tidutamab (formerly XmAb 18087) is a humanised, Fc domain-containing, bispecific monoclonal antibody targeting somatostatin receptor 2 (SSTR2) and a cytotoxic T-cell binding domain (CD3), being developed by Xencor, for the treatment of neuroendocrine tumours (NET) and gastrointestinal stromal tumours (GIST).
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-570-1mg | 1mg | |
| GMP-Bios-ab-570-10mg | 10mg | |
| GMP-Bios-ab-570-100mg | 100mg | |
| GMP-Bios-ab-570-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Tidutamab |
| Target | SSTR2;CD3E |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | ICON;Xencor |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Gastrointestinal stromal tumours;Neuroendocrine tumours |
| Development Tech | na |
About target - SSTR2
1. Protein Somatostatin receptor type 2
2. Gene SSTR2
3. Organism Homo sapiens (Human)
Function
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization.
